变应性鼻炎合并哮喘免疫治疗卫生经济学分析

陈建军; 项济生; 王彦君; 施秋梅; 檀慧芳; 孔维佳

doi:10.13201/j.issn.1001-1781.2013.17.009

变应性鼻炎合并哮喘免疫治疗卫生经济学分析

- 华中科技大学同济医学院附属协和医院耳鼻咽喉科(武汉, 430022)
基金项目:
国家自然科学基金青年基金项目 (No:30901659)

科技部十一五支撑计划 (No:2007BAI18B15)

详细信息

通讯作者: 陈建军,E-mail:ylly80331@163.com

中图分类号: R765.21

收稿日期: 2013-03-25

Health economics analysis of specific immunotherapy in allergic rhinitis accompanied with asthma

- Department of Otorhinolaryngology, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China

More Information

Corresponding author: CHEN Jianjun, E-mail: ylly80331@163.com

Received Date: 25 March 2013

摘要

摘要: 目的:评价以尘螨过敏为主的变应性鼻炎合并哮喘患者行标准化特异性免疫治疗的成本-效果。方法:对临床上40例变应性鼻炎合并哮喘患者,分为免疫治疗组及对照组(单纯药物治疗),进行成本-效果分析,具体指标包括鼻部及哮喘症状得分,生活质量,鼻炎及哮喘主观改善程度的成本-效果及增量成本-效果比,并应用敏感度分析来验证结果的稳定性。结果:免疫治疗组1年治疗成本(6578元)高于对照组(1733.3元),但各项指标的成本-效果比及增量成本效果比均优于对照组,进行价格上下波动10%的敏感度分析,免疫治疗组亦优于对照组。结论:尘螨过敏为主的变应性鼻炎合并哮喘进行特异性免疫治疗成本-效果优于药物治疗组。
- 鼻炎,变应性 /
- 哮喘 /
- 特异性免疫治疗 /
- 成本-效果分析
Abstract: Objective: To investigate the cost-effectiveness of standardized specific immunotherapy(SIT) for allergic rhinitis patients accompanied with asthma(ARAS) in China.Method: Forty ARAS patients sensitized with house dust mite(HDM) were administered with SIT(SIT group) or merely medicine treatment(control group). Alutard dermatophagoides pteronyssinus vaccine from ALK company was used for immunotherapy. The usage of symptom control medicine was according to the ARIA and GINA guideline. Cost-effectiveness ratio(CER) and Incremental cost-effectiveness ratio(ICER) analysis was conducted. The effectiveness was measured in terms of symptom scores, quality of life, objective improvement of rhinitis and asthma. Sensitive analysis was conducted to verify the stability of the results.Result: The cost of SIT group for 1 year(6 578 yuan) was higher than that of control group(1 733.3 yuan), while the cost-effectiveness ratio and incremental cost-effectiveness ratio of SIT group were significant better than that of control group in all items. CER was 1 686.7 yuan in SIT group compared with 3 466.6 yuan in control group for nasal symptom scores, 4 698.6 yuan in SIT group compared with 5 777.8 yuan in control group for asthma symptom scores, 3 462.1 yuan in SIT group compared with 8 666.7 yuan in control group. The sensitive analysis of the price 10 percent higher or lower showed the same results.Conclusion: The cost-effectiveness of specific immunotherapy(SIT) for mite sensitized ARAS patients was better than that of merely medicine treatment.
- rhinitis,allergic /
- asthma /
- specific immunotherapy /
- costeffectiveness analysis

HTML全文

参考文献(7)

[1]	中华医学会耳鼻咽喉科学分会.变应性鼻炎的诊治原则和推荐方案[J].中华耳鼻咽喉头颈外科杂志,2005,40(3):166-167.
[2]	陈建军,孔维佳,项济生,等.变应性鼻炎伴哮喘患者特异性免疫治疗的疗效分析[J].临床耳鼻咽喉头颈外科杂志,2010,24(2):57-59.
[3]	BLAISS M S.Allergic rhinitis:Direct and indirect costs[J].Allergy Asthma Proc,2010,31:375-380.
[4]	DONAHUE J G,GREINEDER D K,CONNOR-LACKE L,et al. Utilization and cost of immunotherapy for allergic asthma and rhinitis[J]. Ann Allergy Asthma Immunol,1999, 82:339-347.
[5]	SCHÄDLICH P K, BRECHT J G. Economic Evaluation of Specific Immunotherapy Versus Symptomatic Treatment of Allergic Rhinitis in Germany[J]. Pharmacoeconomics, 2000,17:37-52.
[6]	DURHAM S R, WALKER S M, VARGA E M, et al. Long-term clinical efficacy of grass-pollen immunotherapy[see comments] [J]. N Engl J Med,1999,341:468-475.
[7]	GUILBERT T W, MORGAN W J, ZEIGER R S, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma[J]. N Engl J Med,2006,354:1985-1997.